Taiwan Biomaterial Co., Ltd.

Total Valuation

Taiwan Biomaterial Co., Ltd. carries a market capitalization of 1.60B, placing it among publicly traded companies globally. Its enterprise value stands at 1.63B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Taiwan Biomaterial Co., Ltd. currently has 42.00M shares outstanding.

Valuation Ratios

Taiwan Biomaterial Co., Ltd. trades at a trailing price-to-earnings ratio of 32.85. The price-to-sales ratio is 8.78, and the price-to-book ratio stands at 3.93.

Enterprise Valuation

On an enterprise value basis, Taiwan Biomaterial Co., Ltd. trades at an EV/EBITDA multiple of 26.83 and an EV/FCF ratio of 31.00. The EV/Sales ratio of 7.41 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 26.83 provides insight into valuation relative to core operating earnings.

Financial Position

Taiwan Biomaterial Co., Ltd. maintains a current ratio of 8.53, meaning it holds 8.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.68, indicating elevated leverage, while an interest coverage ratio of 82.09 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taiwan Biomaterial Co., Ltd. posts a return on equity of 12.73 and a return on invested capital of 8.56.

Stock Price Statistics

Taiwan Biomaterial Co., Ltd.'s stock has gained approximately 2.15054% over the past 52 weeks. The 50-day moving average sits at 38.79, while the 200-day moving average is 47.68.

Income Statement

Over the trailing twelve months, Taiwan Biomaterial Co., Ltd. generated 220.40M in revenue and converted that into 58.93M in net income, yielding earnings per share of 1.42. EBITDA reached 60.83M, while operating income came in at 60.83M.

Balance Sheet

Taiwan Biomaterial Co., Ltd. holds 355.91M in cash and equivalents against 52.59M in total debt, resulting in a net debt position of -258.40M. Total book value stands at 492.42M, with working capital of 413.89M providing operational flexibility.

Cash Flow

Taiwan Biomaterial Co., Ltd. produced 48.77M in operating cash flow over the past twelve months. After subtracting -3.14M in capital expenditures, free cash flow totaled 45.63M - equivalent to 1.10 per share.

Margins

Taiwan Biomaterial Co., Ltd. operates with a gross margin of 61.16, reflecting its pricing power and cost economics. The operating margin of 27.60 and net profit margin of 26.74 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Taiwan Biomaterial Co., Ltd.'s most recent stock split took place on December 20, 2021 with a 500:517 split ratio.

Scores

Taiwan Biomaterial Co., Ltd. posts an Altman Z-Score of 12.37, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.